Certuity LLC Has $742,000 Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Certuity LLC raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,199 shares of the medical equipment provider’s stock after buying an additional 252 shares during the period. Certuity LLC’s holdings in Intuitive Surgical were worth $742,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ISRG. Portside Wealth Group LLC raised its stake in shares of Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after acquiring an additional 3,054 shares in the last quarter. Kades & Cheifetz LLC acquired a new stake in Intuitive Surgical in the fourth quarter valued at $230,000. Blair William & Co. IL increased its stake in shares of Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after purchasing an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Intuitive Surgical by 21.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after purchasing an additional 129,194 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $370.62 on Wednesday. The company has a market cap of $131.46 billion, a price-to-earnings ratio of 66.90, a PEG ratio of 4.83 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The stock has a fifty day moving average price of $385.96 and a 200-day moving average price of $348.19.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the business posted $1.00 earnings per share. Intuitive Surgical’s revenue was up 11.5% compared to the same quarter last year. Research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the transaction, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,168,656.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the sale, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,168,656.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 226,967 shares of company stock worth $87,848,586. Corporate insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Citigroup boosted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Jefferies Financial Group increased their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Raymond James upped their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Stifel Nicolaus raised their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Royal Bank of Canada increased their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.